Abstract
Get full access to this article
View all access options for this article.
References
1.Highlights of prescribing information . ARICEPT®. Available at: http://www.aricept.com/assets/pdf/AriceptComboFullPIFebruary2012.pdf (accessed 5 March 2013 ), pp. 7 –11 .
2.Full U.S. prescribing information . Razadyne. Available at: www.razadyneer.com/sites/default/files/shared/pi/razadyne_er.pdf (accessed 5 March 2013 ), pp. 2 –4 .
3.Prescribing information . Exelon®. Available at: www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf (accessed 5 March 2013 ), pp. 13 –16 .
4.Namenda® full prescribing information . Available at: www.frx.com/pi/namenda_pi.pdf (accessed 5 March 2013 ), pp. 3 –8 .
5.Evaluating prescription drugs used to treat: Alzheimer’s Disease . Consumer Reports, May 2012 , p. 3 .
6.Five FDA approved Alzheimer’s drugs . (Research Center, Science & Progress Treatment Horizon section). Available at: www.alz.org/research/science/alzheimers_disease_treatments.asp (accessed 5 March 2013 ).
7.A primer on Alzheimer’s disease and the brain . NIH Alzheimer’s Disease Progress Report, 2011–2012, p. 9 . Available at: www.nia.nih.gov/alzheimers/publication/2010-alzheimers-disease-progress-report-deeper-understanding/brief-primer (accessed 5 March 2013 ).